Key Drivers
- Cash Cushion
- Loss Expansion
- Weak Conversion
AIAI Summary
PLSE should now be viewed as a concentrated, cash-backed bet on the nPulse cardiac pivotal readout rather than a broad platform story, with upside dependent on clean enrollment and follow-up data but meaningful downside if execution slips or dilution arrives before commercialization.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Loss Expansion
- •Weak Conversion
PLSE has a strong cash-rich, low-debt balance sheet, but its tiny revenue base, persistent large losses, negative cash flow, and extreme valuation make the stock highly speculative.
Price Behavior
Key Price Behavior Insights:
- •Breakout surge
- •Quick retracement
- •Nearby support
PLSE is modestly higher over the last month after a sharp breakout above its prior price band, but the move to $27.10 was quickly retraced, leaving the stock constructive yet volatile with resistance near $27.10 and support around $23.90-$24.00.
Sharp breakout to $27.10 followed by a quick pullback showed elevated volatility
Sentiment & News
Key News Insights:
- •nPulse focus
- •Clinical momentum
- •Insider buying
Pulse Biosciences is increasingly centered on its nPulse cardiac catheter program, with encouraging clinical updates, a Buy rating upgrade, and insider buying offsetting a quarterly loss and revenue miss.
The update is modestly positive for the stock, as clinical progress and insider support strengthen the story despite ongoing earnings and revenue pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings